A Brazilian entity has committed $240 million to establish a generic drug manufacturing plant in Nigeria, announced Prof. Muhammad Ali Pate, Minister of Health and Social Welfare, during a ministerial sectoral update on Friday.
The investment aims to enhance Nigeria’s healthcare value chain and promote the local production of essential medical supplies. This move is expected to reduce Nigeria’s dependence on imported pharmaceuticals and medical devices, create job opportunities, and retain economic value within the country.
“This initiative aligns with our broader agenda to revitalize the healthcare sector and improve access to quality healthcare for all Nigerians,” said Pate. “By fostering domestic production of generic drugs and medical supplies, we can enhance healthcare delivery, promote self-sufficiency, and drive economic growth.”
Prof. Pate also highlighted the significant shift in the production of test kits within Nigeria, noting the emergence of three entities poised to manufacture these essential tools. One facility is already operational in Lagos, with two more expected to start soon. This development marks a departure from Nigeria’s 25-year reliance on imported test kits and underscores the growing confidence in Nigeria’s potential as a hub for pharmaceutical production and healthcare innovation.
The minister further revealed that the government has signed strategic agreements with all 36 states and the Federal Capital Territory (FCT), endorsed by the President, to enhance public-private collaboration in the healthcare sector.
“The policy changes initiated by the President are now fostering domestic production, with more advancements on the horizon,” Pate added.
This investment represents a significant step forward in Nigeria’s efforts to build a robust and self-sufficient healthcare system, ultimately improving the quality and accessibility of healthcare for all Nigerians.
